BioDrugs (2017) 31:369–377 DOI 10.1007/s40259-017-0233-6 OR IGINAL RESEARCH ARTIC L E Efﬁcacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis 1 2 3 4 • • • • Won Park Chang-Hee Suh Seung Cheol Shim Francisco Fidencio Cons Molina 5 6 7 • • • Slawomir Jeka Francisco G. Medina-Rodriguez Pawel Hrycaj 8 9 10 11 • • • • Piotr Wiland Eun Young Lee Pavel Shesternya Volodymyr Kovalenko 12 13 14 • • • Leysan Myasoutova Marina Stanislav Sebastiao Radominski 1 15 16 16 • • • • Mie Jin Lim Jung-Yoon Choe Sang Joon Lee Sung Young Lee 16 17 Sung Hwan Kim Dae Hyun Yoo Published online: 9 June 2017 The Author(s) 2017. This article is an open access publication Abstract the RCT and switched to CT-P10 during the OLE (‘switch Background CT-P10 is a biosimilar candidate of innovator group’). rituximab (RTX) that demonstrated a comparable clinical Methods Patients who completed the RCT were recruited. proﬁle to RTX in a phase I randomized controlled trial Based on the Disease Activity Score using 28 joints (RCT) in rheumatoid
BioDrugs – Springer Journals
Published: Jun 9, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera